Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02326844
Title BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

ovarian cancer



Age Groups: adult
Covered Countries USA

No variant requirements are available.